FDA ApprovalThe likelihood of FDA approval for Reproxalap is considered high, as it is seen as a differentiated DED drug with a disease-modifying mechanism.
Financial PositionThe company ended the quarter with approximately $90 million in cash, which is considered sufficient to fund operations into 2027.
Partnership OpportunitiesIf approved, Abbvie is expected to opt in for a $200M partnership, which is crucial for gaining patient access and reimbursement in the competitive DED space.